Clinical Context
A typical patient is a 42-year-old with moderate to severe Crohn disease or rheumatoid arthritis experiencing inadequate response to conventional therapy who presents to an infusion center for biologic therapy. The patient has a confirmed order for J1745 (infliximab, brand, 10 mg vial) with dose calculated based on weight (for example, 5 mg/kg given as a 100 mg or 200 mg dose depending on vial count) and scheduled infusion times at weeks 0, 2, and 6 for induction, then every 8 weeks for maintenance. The clinical workflow includes verification of prior authorization and benefit eligibility with payors (for example, Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, Medicare), screening for active infections (including tuberculosis), baseline laboratory testing (CBC, CMP, hepatitis B surface antigen), evaluation for contraindications (active infection, hypersensitivity to murine proteins), IV line placement, premedication as indicated (antihistamines, acetaminophen, corticosteroids), administration of the reconstituted and diluted infliximab infusion over the recommended time (typically 2 hours for first infusion, may be shortened for subsequent infusions per protocol), monitoring for infusion reactions during and for at least 1–2 hours post-infusion, documentation of lot number and expiration for each vial of J1745, and billing of the drug per 10 mg units administered with appropriate modifier(s) reflecting service circumstances. The typical site of service is an outpatient infusion center, hospital outpatient department, or physician office equipped for IV biologic administration. Patient education includes potential adverse effects (infusion reactions, increased infection risk) and instructions to seek urgent care for severe symptoms.